 |
18th Annual Award Recipient
Hagop M. Kantarjian, M.D.
Professor of Medicine
Chairman, Department of Leukemia
UT MD Anderson Cancer Center
Houston, TX
|
Dr. Kantarjian delivered his award lecture titled
Leukemia Research and Progress - A Look Back at the Future, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Tuesday, April 9, 2013. Visit the
AACR Annual Meeting 2013 page for more information on the Annual Meeting.
The Award and Lecture
This award was established in 1996 to recognize outstanding achievements in clinical cancer research. It is named for the late Dr. Joseph H. Burchenal, honorary member and past president of the AACR, and a major figure in clinical cancer research and chemotherapy.
The winner of the 18th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research gave a 50-minute lecture during the AACR Annual Meeting 2013, in Washington, DC, USA (April 6-10, 2013), received an honorarium of $10,000, and was given support for the winner and a guest to attend the Annual Meeting.
Eligibility
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Selection
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's achievements in clinical cancer research. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Supporter
Generously supported by Bristol-Myers Squibb.
Questions?
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
awards@aacr.org
SPOTLIGHT
 |
17th Annual Recipient
Lawrence H. Einhorn, M.D.
Distinguished Professor of Medicine
Indiana University
Indianapolis, IN
|
Dr. Lawrence H. Einhorn (center) delivered his award lecture titled, Curing Testicular Cancer: Present Studies and Future Challenges, at the AACR Annual Meeting 2012 in Chicago, IL. Dr. Einhorn recieved his award from Dr. Joseph R. Bertino, past AACR President (right) and Dr. Renzo Canetta of Bristol-Myers Squibb (right).
________________________________________________________________________________________
Dr. Lawrence H. Einhorn’s legacy will forever be associated with transforming the areas of testicular cancer treatment and survival. Prior to Dr. Einhorn’s breakthrough in the treatment of testicular cancer, diagnosis with this disease was a death sentence. At that time, patients had approximately a 10 percent chance of survival. This changed, however, once Dr. Einhorn suggested the use of platinum-based chemotherapy as a means to treat testicular cancer, increasing survival rates up to 80 percent at the time. Dr. Einhorn discovered that by treating patients with cisplatinum, he could induce DNA cross-linking within testicular cancer cells, ultimately resulting in death of the cancer cells. As a result of this observation, survival rates for patients with germ cell cancers have increased rapidly to nearly 95 percent in men with early-stage disease as well as with patients treated with chemotherapy.
Dr. Einhorn, with his novel treatment paradigm, has been particularly notable as he was the clinician involved in treating Lance Armstrong, seven-time winner of the Tour de France and cancer advocate. As a result of Dr. Einhorn’s expertise and foresight, Armstrong is now a survivor of stage 3 testicular cancer that was initially accompanied by abdominal, brain and lung metastasis. To this day, Dr. Einhorn remains involved in Armstrong’s commitment to cancer awareness and was previously appointed as the first Lance Armstrong Foundation professor of oncology in 2006. Most recently, Dr. Einhorn has continued his fight against the many diseases characterized as cancer by investigating combinatorial drug treatment strategies within numerous clinical trials focused on germ cell cancers and solid tumors, especially those associated with high-risk lung cancer.
Dr. Einhorn received his M.D. from the University of Iowa Medical School. Afterward, he conducted his fellowships at MD Anderson and Indiana University Medical Center. He has published more than 470 peer-reviewed articles and currently serves as distinguished professor of medicine at the Indiana University School of Medicine. Throughout his career, Dr. Einhorn’s accomplishments have been recognized with multiple awards including the Living Legends Award from the Indiana Historical Society, the Kettering Prize from General Motors, and AACR’s Richard and Hinda Rosenthal Foundation Award for Cancer Research, among others. Dr. Einhorn served as president of the American Society of Clinical Oncology (2000-2001) and is a current member of the ASCO Cancer Foundation. He has presented his work on countless occasions, is a member of many professional societies, and has previously been elected to both the prestigious American Philosophical Society and National Academy of Sciences.